China CDE Greenlights Phase III Trial of Olverembatinib for SDH-Deficient GIST
Tuesday, 11 June 2024, 00:04
Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE
China's CDE grants approval for a global Phase III study of Olverembatinib in treating patients with SDH-deficient GIST.
This development brings hope for enhancing treatment options and addressing the needs of individuals with this rare form of gastrointestinal stromal tumor.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.